TX
TXG
TXG What 10x Genomics promised, and what happened
Guidance
What management said, and what became of it
8 of 9 judged targets kept · 7 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Quarterly revenue (sequential change) | low-single-digit percentage sequential decline from Q1 FY26 | Mar 2026 | I wouldn't say that things have changed. In fact, I'd just remind you that the Q3 that we're talking about here is consistent with what we said in our Q1 call. | Achieved |
| Full-year revenue | $600 million to $625 million | Dec 2025 | We are raising our full year outlook and now expect 2026 revenue to be in the range of $610 million to $630 million. | Revised Up |
| Atera instrument shipments | approximately 40 units, with initial shipments beginning in the second half of 2026, weighted mostly toward Q4 | Mar 2026 | our shipment outlook of approximately 40 units for the year remains unchanged, as we continue ramping production. | On Track |
The full ledger
Open 10x Genomics’s full ledger
A free account opens 5 company ledgers a month. All 16 tracked commitments, with each call’s wording and source.
The rest of the ledger
Pro opens all 16 tracked commitments for 10x Genomics
Above is what the last two calls moved. Pro adds every quarter's revision, the source quote behind each one, and the topics management has stopped answering.